This is the second financing round of Starne Therapeutics, the mRNA drug developer founded in 2021, after its angel round of financing in December, 2021.
Recenty Starna Therapeutics annoucned its completion of series A financing round worth CNY 150 million (USD 22 .1 million).
This round was led by LYFE Capital (Chinese: 洲嶺资本). Source Code Capital (Chinese: 源码资本)、Hony Capital (Chinese: 弘毅投资) 、Primavera Venture Partners (Chinese: 春华创投) and the existing investors Hillhouse Capital (Chinese: 高瓴创投) and Sherpa Healthcare Partners (Chinese: 夏尔巴投资) also participated in this round.
The funding will be used for expansion of the research center, construction of the test area and advancement of pipelines, thereby to further improve the extra-hepatic RNA delivery technology and broaden the application prospects of mRNA drugs.
Starna Therapeutics specializes in developing RNA innovative drugs to address unmet clincial needs in the area of infectious diseases, tumor immunology and metablic diseases. It has constructed both mRNA design and sythesis platform and mRNA lipid nanopartical (LNP) delivery platform with proprietary intellectual property.